Lung Cancer Content
Rolof Gijtenbeek, ERS 2021: The NVALT 17 Study
We were delighted to talk with Dr Rolof Gijtenbeek (Medical Center Leeuwarden, Leeuwarden, The Netherlands) around his abstract on ‘Randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatin and pemetrexed as first-line therapy for advanced EGFR mutated non-small cell lung cancer, the NVALT 17 study.‘, (Presentation ID 4324) which was presented at […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!